文献速递肿瘤 PET/CT

人工智能在肿瘤[18F]FDG PET显像中的应用:进展与未来趋势——第二部分

Artificial Intelligence for Tumor [18F]FDG PET Imaging: Advancements and Future Trends - Part II.
PubMed 文献 · Semin Nucl Med · 2025-07-18

本文是综述第二部分,探讨人工智能在血液系统肿瘤、泌尿生殖系统肿瘤、黑色素瘤、中枢神经系统肿瘤及儿童肿瘤[18F]FDG PET/CT中的应用。影像组学与机器学习算法被探索用于提高诊断准确性、减少观察者间差异并辅助复杂临床决策。研究间成像方案、分割方法和验证策略的差异持续挑战可重复性,是临床转化的障碍。

要点

  • 人工智能在[18F]FDG PET/CT中用于识别难治性淋巴瘤、评估黑色素瘤假性进展、预测颅外恶性肿瘤脑转移。
  • AI辅助病灶分割、定量特征提取和异质性分析有助于预测治疗反应和长期生存结局。
  • 成像方案、分割方法和验证策略的差异挑战可重复性,是临床转化的障碍。

核心结论

  • 尽管结果令人鼓舞,成像方案、分割方法和验证策略的差异持续挑战可重复性,仍是临床转化的障碍。
  • 本综述强调需要稳健的标准化和前瞻性验证,以确保AI工具在PET成像和临床实践中的可重复性和泛化性。

研究设计与样本

  • 本综述为第二部分,基于第一部分建立的基础,探讨AI在更广泛恶性肿瘤中的应用。

主要发现

  • 影像组学和机器学习算法被探索用于提高诊断准确性、减少观察者间差异并辅助复杂临床决策。
  • AI被探索用于识别难治性淋巴瘤患者、评估黑色素瘤假性进展、预测颅外恶性肿瘤的脑转移。
  • AI辅助病灶分割、定量特征提取和异质性分析有助于改善治疗反应和长期生存结局的预测。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 成像方案、分割方法和验证策略在研究间的差异持续挑战可重复性,仍是临床转化的障碍。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

The integration of artificial intelligence (AI) into [18F]FDG PET/CT imaging continues to expand, offering new opportunities for more precise, consistent, and personalized oncologic evaluations. Building on the foundation established in Part I, this second part explores AI-driven innovations across a broader range of malignancies, including hematological, genitourinary, melanoma, and central nervous system tumors as well applications of AI in pediatric oncology. Radiomics and machine learning algorithms are being explored for their ability to enhance diagnostic accuracy, reduce interobserver variability, and inform complex clinical decision-making, such as identifying patients with refractory lymphoma, assessing pseudoprogression in melanoma, or predicting brain metastases in extracranial malignancies. Additionally, AI-assisted lesion segmentation, quantitative feature extraction, and heterogeneity analysis are contributing to improved prediction of treatment response and long-term survival outcomes. Despite encouraging results, variability in imaging protocols, segmentation methods, and validation strategies across studies continues to challenge reproducibility and remains a barrier to clinical translation. This review evaluates recent advancements of AI, its current clinical applications, and emphasizes the need for robust standardization and prospective validation to ensure the reproducibility and generalizability of AI tools in PET imaging and clinical practice.

来源:Semin Nucl Med,查看原文。版权归原作者所有。

引用

  1. Safarian A, Mirshahvalad SA, Farbod A, et al. Artificial Intelligence for Tumor [18F]FDG PET Imaging: Advancements and Future Trends - Part II. Semin Nucl Med. 2025. PMID: 40683831. doi:10.1053/j.semnuclmed.2025.06.012

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。